Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab and Trastuzumab with T-FEC in Neoadjuvant HER2-Positive Breast Cancer
NCT01855828Phase 2Completed
- Sponsor
- Yale University
- Start
- Sep 2013
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab in HER2-positive breast cancer, sponsored by Yale University. Started Sep 2013; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01855828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01855828.